South Carolina is currently home to 1165 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Columbia and Spartanburg. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/13/2025
Locations: Clinical Research of Rock Hill, Rock Hill, South Carolina
Conditions: Asthma
Register for Updates
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824181
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study dur... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
06/13/2025
Locations: Coastal Pediatric Associates - Charleston- Site Number : 8400014, Charleston, South Carolina
Conditions: Pneumococcal Immunization
Register for Updates
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069
Recruiting
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Zai Lab Site 2012, Charleston, South Carolina
Conditions: SCLC
Register for Updates
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
NCT05865535
Recruiting
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: MUSC Hollings Cancer Center, Charleston, South Carolina
Conditions: Cachexia
Register for Updates
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Recruiting
An open label phase 3 study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Sunpharma site no 31, Greenville, South Carolina
Conditions: Psoriatic Arthritis
Register for Updates
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT04485013
Recruiting
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Cancer
Register for Updates
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
NCT05268614
Recruiting
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/12/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Oropharyngeal Squamous Cell Carcinoma
Register for Updates
A Study of Mosliciguat in PH-ILD
NCT06635850
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Register for Updates
CGM for Management of Type 2 Diabetes in Pregnancy
NCT06628453
Recruiting
The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are: 1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
06/11/2025
Locations: Prisma Health Greenville Memorial Hospital, Greenville, South Carolina
Conditions: Type 2 Diabetes Mellitus (T2DM), Pregnancy
Register for Updates
Young Adult Tobacco/Nicotine and Cannabis Co-use
NCT06239350
Recruiting
The goal of this project is to better understand the relationship between tobacco/nicotine and cannabis using behavioral economics during a tobacco/nicotine quit attempt. All participants will receive tobacco/nicotine cessation treatment (smoking and/or vaping treatment) for 12 weeks. To qualify, participants must be between the ages of 18-25 and use tobacco products (smoke cigarettes and/or vape nicotine) and use cannabis (in any form). Participants do not need to be interested in quitting cann... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
06/11/2025
Locations: Medical University of South Carolina - Charleston, Charleston, South Carolina
Conditions: Tobacco Use Disorder, Nicotine Dependence
Register for Updates
Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness
NCT05362370
Recruiting
The purpose of this study is to confirm the safety, performance and effectiveness of Stryker's PEEK Customized Implants when used for the augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton. The study is designed as a prospective, multi-center trial with a long-term follow-up (24 months) of study participants.
Gender:
ALL
Ages:
42 months and above
Trial Updated:
06/11/2025
Locations: Medical University of South Carolina, Oral & Maxillofacial Surgery, 173 Ashley Avenue, Charleston, USA, Charleston, South Carolina
Conditions: Cranioplasty, Craniofacial Abnormalities, Craniofacial Injuries
Register for Updates
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
NCT05277168
Recruiting
The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Prisma Health, Greenville, South Carolina
Conditions: Advanced Solid Tumors
Register for Updates